Methylene blue containing compounds for the treatment of methaemoglobinaemia
AssigneeWis Ta Laboratories Ltd.
InventorsCharles Robert Harrington, Mohammad Arastoo, Michael Philip Mazanetz, Helen Shiells, John Mervyn David Storey, Claude Michel Wischik
Life of this patent
Estimating the term…
Abstract
The invention provides novel methods of treating methaemoglobinaemia orally in a subject, which methods comprise orally administering to said subject a methylthioninium (“MT”) containing salt of the following formula: wherein each of HnA and HnB (where present) are protic acids which may be the same or different, and wherein p=1 or 2; q=0 or 1; n=1 or 2; (p+q)×n=2, or a hydrate or solvate thereof. The administration should provide a total daily oral dose of 4 mg to 60 mg of MT to the subject per day.
Claims26
A method of treating methaemoglobinaemia in a subject,
- which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,
- wherein said administration provides a total daily oral dose of 4 mg to 60 mg of MT to the subject per day, optionally split into 2 or more doses,
- wherein the MT-containing compound is an LMTX compound of the following formula:
- wherein each of HnA and HnB (where present) are protic acids which may be the same or different,
- and wherein p=1 or 2;
- q=0 or 1;
- n=1 or 2;
- (p+q)×n=2,
- or a hydrate or solvate thereof.
Dependencies are inferred from the claim text.